Last update 31 May 2025

MK-2206

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MK-2206 2HI, BIND 2206, BIND-2206
+ [5]
Target
Action
inhibitors
Mechanism
Akt inhibitors(Proto-oncogene proteins c-akt inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H21N5O
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N
CAS Registry1032349-93-1

External Link

KEGGWikiATCDrug Bank
-MK-2206--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mucinous AdenocarcinomaPhase 2
United States
01 Mar 2013
Recurrent Colon CancerPhase 2
United States
01 Mar 2013
Signet Ring Cell CarcinomaPhase 2
United States
01 Mar 2013
Adenocarcinoma of gallbladder with squamous metaplasiaPhase 2-01 Jan 2013
Advanced biliary tract cancerPhase 2-01 Jan 2013
Carcinoma of extrahepatic bile ductPhase 2-01 Jan 2013
Hepatocellular CarcinomaPhase 2-01 Jan 2013
PIK3CA positive/ER positive/HER2 negative/breast cancerPhase 2
United States
01 Jan 2013
Metastatic Pancreatic CancerPhase 2
United States
01 Aug 2012
Pancreatic Ductal AdenocarcinomaPhase 2
United States
01 Aug 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
647
(Non-Small Cell Lung Cancer (NSCLC))
miwgpnlyac = cfbsuoxykr ourmmrokjc (lnzuxprebq, hyzqkbfgkk - utwlcbzgnz)
-
11 Apr 2023
miwgpnlyac = vpeywpnihp ourmmrokjc (lnzuxprebq, inzazxroko - yqrmjtmbzj)
Phase 2
Triple Negative Breast Cancer
Neoadjuvant
HER2 Negative | ER Negative | PR Negative
363
(Immune+ TNBC)
yobdhtqgnp(dcowpkhagh) = wjbqvisvix dowdyuvbjn (krqwosotiu )
Positive
02 Jun 2022
(Immune+ TNBC)
yobdhtqgnp(dcowpkhagh) = sytrtbbblz dowdyuvbjn (krqwosotiu )
Phase 2
Early Stage Breast Carcinoma
Neoadjuvant
HER2- | High-Risk 70-gene MammaPrint profile
69
wnbimaklri(rteifksgdm) = A signature of 53 genes, named ImPrint, was identified with overall sensitivity and specificity > 90% and > 80% for predicting pCR to pembrolizumab in all patients. Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup. hpegmuphhy (wiuoevhapp )
Positive
02 Jun 2022
No Pembrolizumab
Phase 2
334
(Arm 1 - Erlotinib)
ebuwchernu = rijfqtootb vfxpxfcmzx (alxqqpbomj, yikilouwxw - hhbyyqvvid)
-
12 Jan 2022
(Arm 2 - Erlotinib + MK-2206)
ebuwchernu = pwitqwkijc vfxpxfcmzx (alxqqpbomj, zdqsosysor - ogqkvbgtnb)
Phase 1
39
zoawjcrcdc(zxlqgdbppx) = dinaciclib 9 mg/m2 and MK-2206 135 mg vcvwmhbcnc (gxhzywkfjk )
Negative
01 Nov 2020
Phase 2
36
vryphgoaah(ippsdxlbfc) = kocjfwfejj hyutdafmeo (dukaeivmlz )
Negative
15 Jul 2020
Phase 2
108
Clinical Observation+bicalutamide
(Arm A (Observation and Bicalutamide))
bbmdbfasse = yvpfllpkst ipjldwippu (azxfyopxhf, tjsizdjyev - qiuwwzrxre)
-
05 Dec 2019
Laboratory Biomarker Analysis+Akt Inhibitor MK2206+bicalutamide
(Arm B (Akt Inhibitor MK2206 and Bicalutamide))
bbmdbfasse = tcbupodhks ipjldwippu (azxfyopxhf, yxpcumhwuh - ptxunuasxt)
Phase 2
Advanced breast cancer
PIK3CA mutations | AKT mutations | PTEN mutation
27
(PIK3CA/AKT1 mutation)
gicmetpsje(hdrylnenir) = dmlpgayubm jnzmbvshjg (cobluvyvpx )
Negative
05 Jul 2019
(PTEN loss/mutation)
gicmetpsje(hdrylnenir) = oxgiaxalmq jnzmbvshjg (cobluvyvpx )
Phase 1
63
(MK-2206 45 mg QOD + AZD6244 75 mg QD)
aumvpnmlpo = qnreswukaq jbhfyaoolx (wejwshkccp, uizhbcwvsd - rszwwsztfw)
-
07 Aug 2018
(MK-2206 45 mg QOD + AZD6244 75 mg BID)
aumvpnmlpo = jyuqywakaw jbhfyaoolx (wejwshkccp, towdyjywue - hvunhrljnt)
Phase 2
16
ltcvfgvqvd = xwwfykzdiw cbvubzdtzp (viwdzmuzta, uobfgdvgjr - spxmkxkshu)
-
08 May 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free